Advancements in MCRPC Treatment: SPLASH Trial Insights

This chapter explores the SPLASH trial updates on lutetium INT for patients with metastatic castrate-resistant prostate cancer, comparing its efficacy to standard androgen receptor pathway inhibitors. Key findings highlight a significant reduction in disease progression, the importance of patient demographics in treatment decisions, and the need for further research on dosing and personalized approaches.